Good morning, everyone, and nice to see you again. A warm and shiny sun is enveloping the Pharmalot campus, which is exceedingly quiet as our shortest person sleeps in and the other short one has departed for the usual gainful employment. Moreover, the official mascots are snoozing happily in various corners. As for us, yes, we are firing up the coffee kettle once again and digging in for another busy day of phone calls, meetings, and, of course, research. Meanwhile, here are some tidbits to help you on your own journey. Hope it goes well, and please do keep in touch …

Abbvie (ABBV) is claiming the National Health Service in England breached procurement rules during a process seeking suppliers for hepatitis C treatment, Health Service Journal reports. The procurement, described by NHS England as the single largest medicines procurement ever done by the NHS, was launched in the spring and its estimated value is in the hundreds of millions of dollars. The procurement was launched in a bid to lower the cost of hepatitis C drugs, but Abbvie alleged NHS England breached its duty to treat all bidders fairly.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy